The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma

American Surgeon

Volumn 69, Issue 2, 2003, Pages 117-124

  Wudel Jr , L James ^a   Delbeke, Dominique ^a   Morris, David ^a   Rice, Michael ^a   Washington, Mary Kay ^a   Shyr, Yu ^a   Pinson, C Wright ^a   Chapman, William C ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; BIOPSY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DECISION TREE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; NECROSIS; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STANDARD; TUMOR RECURRENCE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BIOPSY; CARCINOMA, HEPATOCELLULAR; DECISION TREES; FEMALE; FLUORODEOXYGLUCOSE F18; HEPATECTOMY; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037313611     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-1495 (Pubitemid 17038084)
2. Monakhov NK, Neistadt EL, Shavlovskii MM, et al. Physiochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. J Natl Cancer Inst 1978;61:27-34.
3. Knox WE, Jamdar SC, Davis PA. Hexokinase, differentiation, and growth rates of transplanted tumors. Cancer Res 1970;30:2240-2244
4. 18F]fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-1329 (Pubitemid 13218489)
5. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988;150:189-197 (Pubitemid 18027033)
6. Wahl RL. Positron emission tomography: Applications in oncology. In: Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Edinburgh: Churchill Livingstone Inc, 1994; pp 801-820
7. Whal RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation. Radiology 1994;191:371-377
8. Vitola JV, Delbeke D, Sandler MPS, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-26 (Pubitemid 26028187)
9. 18F]fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 1996;78:2216-2222
10. Delbeke D, Vitola JV, Sandler MPS, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-1201 (Pubitemid 27332611)
11. 18F]2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154-1161
12. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues. Cancer Res 1955;15:105-108
13. Weber G, Morris HP. Comparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumors of different growth rates. Cancer Res 1963;23:987-994
14. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339
15. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET. J Nucl Med 1995;36:1811-1817
16. Messa C, Choi Y, Hoh CK, et al. Quantification of glucose utilization in liver metastases: Parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992;16:684-687
17. Nzeako UC, Goodman ZD, Ishak KG. Comparison of tumor pathology with duration of survival of North American patients with hepatocellular carcinoma. Cancer 1995;76:579-588
18. Kaczynski J. Prevention of cirrhosis is the best measure against hepatocellular cancer. Lakartidningen 1999;96:338-341
19. Weber G, Cnatero A. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues. Cancer Res 1955;15:105-108
20. Johnson D, Martin WH, Delbeke D. Clinical applications in oncology: Other gastrointestinal tumors. In: Delbeke D, Martin WH, Patton JA, Sandler MP, eds. Practical FDG imaging: A teaching file. New York: Springer-Verlag, 2002; pp 236-279
21. Khan MA, Combs CS, Brunt EM. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Heptol 2000;792-797
22. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-515 (Pubitemid 28224319)
23. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET. J Nucl Med 1995;36:1811-1817
24. Rose AT, Rose DM, Pinson CW, Wright JK, Blair T, Blanke C, Delbeke D, Debelak JP, Chapman WC. Hepatocellular carcinoma outcome based on indicated treatment strategy. Am Surg 1998;64:1122-1135 (Pubitemid 28539121)
25. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-1969
26. 18F]FDG positron emission tomography. J Comput Assist Tomogr 1990;14:370-374 (Pubitemid 20162556)
27. Sarasin F, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of respectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology 1998;28:436-442 (Pubitemid 28363671)